ABSTRACT
We present a case of systemic lupus erythematosus complicated by pancytopenia and visceral leishmaniasis in Spain. The literature on opportunistic infection in lupus erythematosus is reviewed.Leishmaniasis is a group of infections caused by the protozoa Leishmania, which is endemic in the Mediterranean basin. These opportunistic infections are an emerging entity in immunosuppressed patients. The use of immunosuppressive treatment in systemic lupus erythematosus modifies natural defense patterns and increases the risk of visceral leishmaniasis in endemic areas.
Subject(s)
Leishmaniasis, Visceral/etiology , Lupus Erythematosus, Systemic/complications , Adult , Amphotericin B/administration & dosage , Amphotericin B/therapeutic use , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Female , Follow-Up Studies , Humans , Immunosuppression Therapy/adverse effects , Leishmaniasis, Visceral/diagnosis , Leishmaniasis, Visceral/drug therapy , Lupus Erythematosus, Systemic/drug therapy , Lupus Erythematosus, Systemic/immunology , Pancytopenia/etiology , Time FactorsABSTRACT
Presentamos un caso de lupus eritematoso sistémico complicado con pancitopenia y leishmaniasis visceral ocurrido en España. A propósito del mismo, realizamos una revisión bibliográfica sobre infecciones oportunistas en el lupus eritematoso sistémico. La leishmaniasis es un grupo de enfermedades causadas por el protozoo Leishmania, endémica en la cuenca mediterránea y de carácter oportunista y emergente en pacientes inmunodeprimidos. El uso de inmunosupresores en el tratamiento del lupus eritematoso sistémico induce modificaciones en la defensa natural, aumentando el riesgo de aparición de leishmaniasis visceral en zonas endémicas
We present a case of systemic lupus erythematosus complicated by pancytopenia and visceral leishmaniasis in Spain. The literature on opportunistic infection in lupus erythematosus is reviewed. Leishmaniasis is a group of infections caused by the protozoa Leishmania, which is endemic in the Mediterranean basin. These opportunistic infections are an emerging entity in immunosuppressed patients. The use of immunosuppressive treatment in systemic lupus erythematosus modifies natural defense patterns and increases the risk of visceral leishmaniasis in endemic areas
